Baker Bros. Advisors Lp - Net Worth and Insider Trading
Baker Bros. Advisors Lp Net Worth
The estimated net worth of Baker Bros. Advisors Lp is at least $20.6 Billion dollars as of 2024-07-27. Baker Bros. Advisors Lp is the Director, 10% Owner of Seagen Inc and owns about 42,970,781 shares of Seagen Inc (SGEN) stock worth over $9.8 Billion. Baker Bros. Advisors Lp is the Director, 10% Owner of Incyte Corp and owns about 66,793,259 shares of Incyte Corp (INCY) stock worth over $4.6 Billion. Baker Bros. Advisors Lp is also the Director, 10% Owner of BeiGene Ltd and owns about 9,795,129 shares of BeiGene Ltd (BGNE) stock worth over $1.6 Billion. Besides these, Baker Bros. Advisors Lp also holds ACADIA Pharmaceuticals Inc (ACAD) , Alexion Pharmaceuticals Inc (ALXN) , Madrigal Pharmaceuticals Inc (MDGL) , Genomic Health Inc (GHDX) , Rhythm Pharmaceuticals Inc (RYTM) , Entrada Therapeutics Inc (TRDA) , Kiniksa Pharmaceuticals International PLC (KNSA) , BioCryst Pharmaceuticals Inc (BCRX) , Kodiak Sciences Inc (KOD) , Prelude Therapeutics Inc (PRLD) , IGM Biosciences Inc (IGMS) , Intellia Therapeutics Inc (NTLA) , TScan Therapeutics Inc (TCRX) , Talis Biomedical Corp (TLIS) , Mirati Therapeutics Inc (MRTX) , Neoleukin Therapeutics Inc (NLTX) , HOOKIPA Pharma Inc (HOOK) , Atreca Inc (BCEL) , Aceragen Inc (ACGN) , Invitae Corp (NVTAQ) , Bellicum Pharmaceuticals Inc (BLCM) . Details can be seen in Baker Bros. Advisors Lp's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Baker Bros. Advisors Lp has not made any transactions after 2024-03-28 and currently still holds the listed stock(s).
Transaction Summary of Baker Bros. Advisors Lp
Baker Bros. Advisors Lp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Baker Bros. Advisors Lp owns 29 companies in total, including IGM Biosciences Inc (IGMS) , Incyte Corp (INCY) , and Kodiak Sciences Inc (KOD) among others .
Click here to see the complete history of Baker Bros. Advisors Lp’s form 4 insider trades.
Insider Ownership Summary of Baker Bros. Advisors Lp
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
IGMS | IGM Biosciences Inc | 2024-03-28 | director & 10 percent owner |
INCY | Incyte Corp | 2022-03-10 | director & 10 percent owner |
KOD | Kodiak Sciences Inc | 2022-06-06 | director & 10 percent owner |
2022-06-17 | director & 10 percent owner | ||
2022-06-29 | director | ||
2023-10-19 | other: Former 10% Owner | ||
2023-11-14 | director & 10 percent owner | ||
2023-05-24 | 10 percent owner | ||
2021-12-01 | director & 10 percent owner | ||
2020-05-14 | director | ||
2020-03-16 | director | ||
2023-08-17 | 10 percent owner | ||
2017-10-26 | director | ||
2019-04-23 | 10 percent owner | ||
2018-09-13 | 10 percent owner | ||
2018-03-28 | 10 percent owner | ||
2018-01-19 | 10 percent owner | ||
2016-06-09 | 10 percent owner | ||
2017-10-05 | 10 percent owner | ||
2016-08-16 | 10 percent owner | ||
2016-05-11 | 10 percent owner | ||
2012-04-12 | 10 percent owner | ||
2012-04-12 | 10 percent owner | ||
2022-06-10 | director & 10 percent owner | ||
2022-06-13 | director & 10 percent owner | ||
2021-02-23 | director | ||
2022-06-06 | 10 percent owner | ||
2022-05-11 | director & 10 percent owner | ||
2023-12-14 | director |
Baker Bros. Advisors Lp Latest Holdings Summary
Baker Bros. Advisors Lp currently owns a total of 24 stocks. Among these stocks, Baker Bros. Advisors Lp owns 42,970,781 shares of Seagen Inc (SGEN) as of December 1, 2021, with a value of $9.8 Billion and a weighting of 47.83%. Baker Bros. Advisors Lp owns 66,793,259 shares of Incyte Corp (INCY) as of March 10, 2022, with a value of $4.6 Billion and a weighting of 22.3%. Baker Bros. Advisors Lp also owns 9,795,129 shares of BeiGene Ltd (BGNE) as of November 14, 2023, with a value of $1.6 Billion and a weighting of 7.75%. The other 21 stocks ACADIA Pharmaceuticals Inc (ACAD) , Alexion Pharmaceuticals Inc (ALXN) , Madrigal Pharmaceuticals Inc (MDGL) , Genomic Health Inc (GHDX) , Rhythm Pharmaceuticals Inc (RYTM) , Entrada Therapeutics Inc (TRDA) , Kiniksa Pharmaceuticals International PLC (KNSA) , BioCryst Pharmaceuticals Inc (BCRX) , Kodiak Sciences Inc (KOD) , Prelude Therapeutics Inc (PRLD) , IGM Biosciences Inc (IGMS) , Intellia Therapeutics Inc (NTLA) , TScan Therapeutics Inc (TCRX) , Talis Biomedical Corp (TLIS) , Mirati Therapeutics Inc (MRTX) , Neoleukin Therapeutics Inc (NLTX) , HOOKIPA Pharma Inc (HOOK) , Atreca Inc (BCEL) , Aceragen Inc (ACGN) , Invitae Corp (NVTAQ) , Bellicum Pharmaceuticals Inc (BLCM) have a combined weighting of 22.12% among all his current holdings.
Latest Holdings of Baker Bros. Advisors Lp
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
SGEN | Seagen Inc | 2021-12-01 | 42,970,781 | 228.74 | 9,829,136,446 |
INCY | Incyte Corp | 2022-03-10 | 66,793,259 | 68.62 | 4,583,353,433 |
BGNE | BeiGene Ltd | 2023-11-14 | 9,795,129 | 162.54 | 1,592,100,268 |
ACAD | ACADIA Pharmaceuticals Inc | 2023-05-24 | 78,040,810 | 19.14 | 1,493,701,103 |
ALXN | Alexion Pharmaceuticals Inc | 2020-03-18 | 8,002,119 | 182.50 | 1,460,386,718 |
MDGL | Madrigal Pharmaceuticals Inc | 2023-12-14 | 1,979,382 | 284.35 | 562,837,272 |
GHDX | Genomic Health Inc | 2019-04-12 | 7,813,235 | 63.44 | 495,671,628 |
RYTM | Rhythm Pharmaceuticals Inc | 2017-10-05 | 1,878,242 | 49.05 | 92,127,770 |
TRDA | Entrada Therapeutics Inc | 2022-06-06 | 4,865,819 | 17.18 | 83,594,770 |
KNSA | Kiniksa Pharmaceuticals International PLC | 2018-05-29 | 3,000,000 | 26.12 | 78,360,000 |
BCRX | BioCryst Pharmaceuticals Inc | 2016-08-16 | 9,441,849 | 7.85 | 74,118,515 |
KOD | Kodiak Sciences Inc | 2022-06-06 | 17,310,490 | 3.24 | 56,085,988 |
PRLD | Prelude Therapeutics Inc | 2020-09-29 | 9,247,763 | 5.79 | 53,544,548 |
IGMS | IGM Biosciences Inc | 2024-03-28 | 3,753,480 | 11.18 | 41,960,153 |
NTLA | Intellia Therapeutics Inc | 2016-05-11 | 976,214 | 26.48 | 25,850,147 |
TCRX | TScan Therapeutics Inc | 2022-05-11 | 2,784,792 | 7.27 | 20,245,438 |
TLIS | Talis Biomedical Corp | 2021-11-18 | 508,362 | 8.33 | 4,234,655 |
MRTX | Mirati Therapeutics Inc | 2016-06-09 | 30,140 | 58.70 | 1,769,218 |
NLTX | Neoleukin Therapeutics Inc | 2023-08-17 | 280,760 | 3.49 | 979,852 |
HOOK | HOOKIPA Pharma Inc | 2019-04-23 | 82,073 | 6.19 | 508,032 |
BCEL | Atreca Inc | 2023-10-19 | 2,971,128 | 0.09 | 267,402 |
ACGN | Aceragen Inc | 2017-10-26 | 136,431 | 0.38 | 51,844 |
NVTAQ | Invitae Corp | 2018-03-28 | 7,553,553 | 0.00 | 2,266 |
BLCM | Bellicum Pharmaceuticals Inc | 2018-01-19 | 5,813 | 0.07 | 435 |
Holding Weightings of Baker Bros. Advisors Lp
Baker Bros. Advisors Lp Form 4 Trading Tracker
According to the SEC Form 4 filings, Baker Bros. Advisors Lp has made a total of 3 transactions in Seagen Inc (SGEN) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Seagen Inc is the sale of 394,895 shares on December 1, 2021, which brought Baker Bros. Advisors Lp around $63 Million.
According to the SEC Form 4 filings, Baker Bros. Advisors Lp has made a total of 4 transactions in Incyte Corp (INCY) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Incyte Corp is the acquisition of 389,080 shares on March 10, 2022, which cost Baker Bros. Advisors Lp around $28 Million.
According to the SEC Form 4 filings, Baker Bros. Advisors Lp has made a total of 3 transactions in BeiGene Ltd (BGNE) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in BeiGene Ltd is the sale of 1,100,000 shares on November 14, 2023, which brought Baker Bros. Advisors Lp around $199 Million.
More details on Baker Bros. Advisors Lp's insider transactions can be found in the Insider Trading History of Baker Bros. Advisors Lp table.Insider Trading History of Baker Bros. Advisors Lp
- 1
Baker Bros. Advisors Lp Trading Performance
GuruFocus tracks the stock performance after each of Baker Bros. Advisors Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Baker Bros. Advisors Lp is 16.26%. GuruFocus also compares Baker Bros. Advisors Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Baker Bros. Advisors Lp within 3 months outperforms 50 times out of 88 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Baker Bros. Advisors Lp's insider trading performs compared to the benchmark.
Performance of Baker Bros. Advisors Lp
Baker Bros. Advisors Lp Ownership Network
Baker Bros. Advisors Lp Owned Company Details
What does IGM Biosciences Inc do?
Who are the key executives at IGM Biosciences Inc?
Baker Bros. Advisors Lp is the director & 10 percent owner of IGM Biosciences Inc. Other key executives at IGM Biosciences Inc include Principal Accounting Officer Steven Weber , Chief Medical Officer Chris H Takimoto , and Chief Financial Officer Misbah Tahir .
IGM Biosciences Inc (IGMS) Insider Trades Summary
Over the past 18 months, Baker Bros. Advisors Lp made 2 insider transaction in IGM Biosciences Inc (IGMS) with a net purchase of 928,010. Other recent insider transactions involving IGM Biosciences Inc (IGMS) include a net sale of 15,833 shares made by Bruce Keyt , a net sale of 12,222 shares made by Lisa Lynn Decker , and a net sale of 6,306 shares made by George Gauthier .
In summary, during the past 3 months, insiders sold 11,452 shares of IGM Biosciences Inc (IGMS) in total and bought 0 shares, with a net sale of 11,452 shares. During the past 18 months, 173,700 shares of IGM Biosciences Inc (IGMS) were sold and 1,130,933 shares were bought by its insiders, resulting in a net purchase of 957,233 shares.
IGM Biosciences Inc (IGMS)'s detailed insider trading history can be found in Insider Trading Tracker table.
IGM Biosciences Inc Insider Transactions
Baker Bros. Advisors Lp Mailing Address
Above is the net worth, insider trading, and ownership report for Baker Bros. Advisors Lp. You might contact Baker Bros. Advisors Lp via mailing address: 860 Washington Street, 3rd Floor, New York Ny 10014.